Journal of Health Economics and Outcomes Research最新文献

{"title":"Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis.","authors":"Khalidah Alenzi, Abdulrahman Alturaiki, Mohammad Fatani, Saad Alsogair, Arsalan Mohammad Saeed, Ayman Behiry, Ali Almomatin","doi":"10.36469/001c.151864","DOIUrl":"10.36469/001c.151864","url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA) is a chronic autoimmune condition characterized by non-scarring hair loss, with significant psychological, social, and economic implications. In Saudi Arabia, AA prevalence ranges from 2.3% to 13.8%, with early onset and strong familial predisposition. Despite its burden, data on the economic impact of AA in the region remain limited.</p><p><strong>Objectives: </strong>This study assessed the economic burden of AA in the Kingdom of Saudi Arabia from both public payer and societal perspectives, across varying disease severities including mild to moderate, severe, and refractory cases.</p><p><strong>Methods: </strong>A prevalence-based cost-of-illness model was developed using structured literature review, expert input, and primary data collection via questionnaires. The model estimated direct medical costs (drug acquisition, diagnostics, clinic visits), direct nonmedical costs (travel, accommodation), and indirect costs (productivity loss) over 1 year for mild to severe AA and 2 years for refractory cases. Cost data were sourced from official channels (National Unified Procurement Company and the Saudi Food and Drug Authority) and validated using Saudi Amazon and Al-Dawaa pharmacy platforms. Medical costs, including laboratory tests, diagnostic procedures, and all supportive therapies, were obtained from the Ministry of Health.</p><p><strong>Results: </strong>The average annual per-patient cost was SAR 20 703 for mild to moderate AA and SAR 76 957 for severe AA, translating into SAR 5.827 billion and SAR 3.352 billion total burden, respectively. Refractory AA cases incurred cumulative 2-year costs ranging from SAR 102 117 to SAR 167 615 per patient. Indirect costs, primarily due to productivity loss, were the dominant cost driver in mild to moderate AA and remained substantial across all severities.</p><p><strong>Discussion: </strong>Indirect costs, mainly productivity loss, drive the economic burden of AA in Saudi Arabia, with drug costs rising in severe cases. This pattern mirrors findings from global studies.</p><p><strong>Conclusions: </strong>AA imposes a significant financial burden in Saudi Arabia, driven largely by productivity losses and drug acquisition costs. These findings underscore the need for early diagnosis, standardized treatment protocols, and improved access to innovative therapies. Integrated care pathways and national registries are essential to optimize resource allocation and improve patient outcomes.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"253-261"},"PeriodicalIF":2.3,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Evaluation of a Novel MicroRNA-Based Assay to Determine Risk of Late Genitourinary Radiation Toxicity in Patients With Prostate Cancer.","authors":"Jacie T Cooper, John E Schneider","doi":"10.36469/001c.146844","DOIUrl":"10.36469/001c.146844","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is one of the most common malignancies in men, and radiation therapy, most often stereotactic body radiation therapy or conventionally fractionated radiotherapy, is a standard curative treatment for advanced cases. Although genitourinary toxicity is a known side effect, with acute symptoms typically resolving and late toxicity causing lasting harm, individual risk varies substantially. However, no validated tool exists to predict patient-specific toxicity across radiation modalities, leaving treatment decisions to be made without personalized risk insights.</p><p><strong>Objective: </strong>The goal of this analysis was to estimate changes in cost and quality of life associated with reductions in late genitourinary toxicity attributable to personalized radiation therapy in individuals with prostate cancer. Implementation of PROSTOX <i>ultra</i>, a novel microRNA-based assay for toxicity risk assessment with stereotactic body radiation therapy, is expected to enable the personalization of radiation therapy, helping patients avoid toxic effects from specific types of radiation therapy.</p><p><strong>Methods: </strong>This study utilizes a hybrid decision-tree and Markov model approach to estimate the 5-year cost-impact and lifetime cost-effectiveness in prostate cancer patients of PROSTOX <i>ultra</i> vs current treatment standards that do not include toxicity risk assessment. High or low risk assessment influences whether patients receive stereotactic body radiation therapy, conventionally fractionated radiotherapy, or prostatectomy, impacting toxicity-related treatment costs and quality-of-life decrements.</p><p><strong>Results: </strong>Over 5 years, PROSTOX <i>ultra</i> patients totaled <math><mn>47</mn> <mrow><mo> </mo></mrow> <mn>683</mn> <mi>i</mi> <mi>n</mi> <mi>c</mi> <mi>o</mi> <mi>s</mi> <mi>t</mi> <mi>s</mi> <mi>v</mi> <mi>s</mi></math> 67 298 with standard-care risk assessment. Cumulative savings over 5 years were $19 615 per tested patient. Over a lifetime, PROSTOX <i>ultra</i> was expected to save about $24 777 per tested patient while adding 0.24 quality-adjusted life-years compared with patients tested using standard assessment.</p><p><strong>Conclusions: </strong>Model results indicate that toxicity risk assessment with PROSTOX <i>ultra</i> would be cost saving over 5 years compared with standard risk assessment. Cost-effectiveness results show cost savings and quality-adjusted life-year gains over a lifetime, indicating that PROSTOX <i>ultra</i> would be a dominant strategy compared with treatment without risk assessment.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"246-252"},"PeriodicalIF":2.3,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Assessment of the Environmental Impact of Pentaspline Pulsed Field Ablation and Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation.","authors":"Julian Chun, Boris Schmidt, Ines Timmermanns, Steffen Uffenorde, Carla Fernández-Barceló, Tobias Muench, Clare Brooke, Domenico Giovanni Della Rocca","doi":"10.36469/001c.151216","DOIUrl":"10.36469/001c.151216","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) affects 2% to 4.5% of the population. Catheter ablation, a key strategy for paroxysmal AF management, can be achieved through radiofrequency (RFA), cryoablation (CBA), or pulsed field ablation (PFA). While clinical outcomes are well studied, their environmental impact remains underexplored.</p><p><strong>Objectives: </strong>This study modeled the environmental impact of CBA and PFA ablation techniques in Europe, aiming to provide evidence to guide sustainable practices in AF treatment.</p><p><strong>Methods: </strong>An early environmental analysis compared pentaspline PFA (Farapulse system, Boston Scientific) with CBA using a decision-analytic model. The model simulated the patient care pathway from a hospital perspective over a 1-year time horizon, considering index and redo procedures, and complications. The environmental impact, linked to resource use, was measured in kilograms of CO₂ equivalents (kg CO_2eq), incorporating length of stay, intervention time, anesthetic use, and complications. Probabilistic and scenario analyses, including a comparison with RFA, were performed to assess uncertainty and robustness of the results.</p><p><strong>Results: </strong>The environmental analysis showed that PFA resulted in total emissions of 13 899 kg CO_2eq, compared with 16 383 kg CO_2eq for CBA (-2483 kg CO_2eq, -15.2%) per 100 patients. Monte Carlo simulation results confirmed these findings, showing median savings of 2409 kg CO_2eq (95% credible interval: 581-4312 kg). Parameters, such as anesthesia time and anesthetic drug use, were key drivers of the results. In the RFA scenario analysis, PFA yielded a saving potential of -4640 kg (-25%). In Germany, for example, with approximately 24 000 CBA procedures annually, PFA adoption was projected to reduce emissions by 509 723 kg CO_2eq.</p><p><strong>Discussion: </strong>PFA showed potential for reducing emissions by approximately 25 kg CO_2eq per patient compared with CBA, driven by lower resource use. These findings aligned with studies identifying operating rooms and anesthetic drug use as major contributors to hospital emissions. A study limitation was the lack of data on catheter manufacturing and disposal.</p><p><strong>Conclusions: </strong>PFA was expected to reduce emissions compared with CBA in AF patients. Conscious medical device choices can foster more sustainable hospital practices. A full life-cycle analysis of catheters is needed to validate these findings.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"237-244"},"PeriodicalIF":2.3,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying Disease Severity in Health Technology Assessment in Japan: A Retrospective Analysis Using Quality-Adjusted Life-Year Shortfalls.","authors":"Miwa Enami, Akira Yuasa, Shunya Ikeda","doi":"10.36469/001c.147469","DOIUrl":"10.36469/001c.147469","url":null,"abstract":"<p><strong>Background: </strong>Since 2019, Japan has implemented health technology assessments (HTAs) for selected drugs and medical devices. In the HTA system, the incremental cost-effectiveness ratio (ICER), calculated using quality-adjusted life-years (QALYs), is employed to guide price adjustments. However, the current system does not incorporate a quantitative assessment of disease severity.</p><p><strong>Objectives: </strong>This study aimed to evaluate whether severity modifiers based on QALY shortfalls correspond to conditions currently granted special consideration, that is, those eligible for a higher ICER reference value (1.5× the standard), and to explore their implications for Japan's HTA system.</p><p><strong>Methods: </strong>We retrospectively analyzed 32 drugs assessed under Japan's HTA up to March 2025. Absolute shortfall (AS) and proportional shortfall (PS) were calculated using age, sex distribution, and comparator quality-adjusted life expectancy estimates from manufacturer assessments and public assessments. Severity categories were defined as ×1.0 (AS ≤ ×12 or PS ≤0.85), ×1.2 (12 < AS < 18 or 0.85 < PS < 0.95), and ×1.7 (AS ≥18 or PS ≥0.95). The concordance between severity classification and policy-based special consideration was then examined.</p><p><strong>Results: </strong>Twenty-five matched target populations were identified. Mean AS and PS values did not differ significantly between manufacturer and public assessments, although manufacturers tended to report higher shortfalls. All cancer and pediatric cases were classified as ×1.2 or ×1.7, whereas 1 designated intractable disease was classified as having low severity (×1.0). Chronic and infectious diseases fell into higher severity categories despite not currently being subject to special consideration. Weighted mean severity values were comparable to those used in the UK's National Institute for Health and Care Excellence benchmarks.</p><p><strong>Discussion: </strong>The findings revealed both alignment and misalignment between Japan's current HTA policy and severity classification. While cancer and pediatric diseases were consistent with the existing system, some serious diseases might have been overlooked, and the designated intractable disease might not align with quantitative severity criteria.</p><p><strong>Conclusions: </strong>QALY shortfalls may serve as a complementary approach to identifying unmet health needs within Japan's HTA system. To ensure methodological robustness and social acceptance, broader validation, standardized estimation methods, and stakeholder consensus are necessary for effective decision-making.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"229-236"},"PeriodicalIF":2.3,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12677002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying the Public Health Impact of Lyme Disease in Minnesota: A Simulation Analysis of Reported and Unreported Cases.","authors":"Kathleen E Angell, M Jana Broadhurst, Jianghu J Dong, Tzeyu L Michaud, Abraham Degarege, Roberto Cortinas, David M Brett-Major","doi":"10.36469/001c.146618","DOIUrl":"10.36469/001c.146618","url":null,"abstract":"<p><p><b>Background:</b> Lyme disease, the most common vector-borne disease in Minnesota, is estimated to be underreported by a factor of 10. Delayed diagnosis and misdiagnosis may lead to health complications and increased personal and societal costs. Environmental factors can help to predict high disease years, allowing for early intervention to decrease disease burden. <b>Objective:</b> To estimate the health and cost burdens of Lyme disease and the extent to which they could be diminished by public health intervention when high-incidence Lyme disease years are forecasted. <b>Methods:</b> We used 5 two-dimensional Monte Carlo simulations to estimate (1) average annual expected burden of Lyme disease, (2 and 3) average burden in low- and high-incidence years, and (4 and 5) the expected burden saved with public health educational interventions preceding high-incidence years. We employed cases reported to the Minnesota Department of Health adjusted for estimates of underreporting found in the literature. <b>Results:</b> Among an average of 8436 Lyme disease cases annually, 6074 of them were unidentified. High-incidence years saw over 3700 more cases than low-incidence years, with incremental costs to patients and society exceeding <math><mn>3</mn> <mi>m</mi> <mi>i</mi> <mi>l</mi> <mi>l</mi> <mi>i</mi> <mi>o</mi> <mi>n</mi> <mo>.</mo> <mi>W</mi> <mi>e</mi> <mi>e</mi> <mi>s</mi> <mi>t</mi> <mi>i</mi> <mi>m</mi> <mi>a</mi> <mi>t</mi> <mi>e</mi> <mi>d</mi> <mi>t</mi> <mi>h</mi> <mi>a</mi> <mi>t</mi> <mi>p</mi> <mi>u</mi> <mi>b</mi> <mi>l</mi> <mi>i</mi> <mi>c</mi> <mi>h</mi> <mi>e</mi> <mi>a</mi> <mi>l</mi> <mi>t</mi> <mi>h</mi> <mi>e</mi> <mi>d</mi> <mi>u</mi> <mi>c</mi> <mi>a</mi> <mi>t</mi> <mi>i</mi> <mi>o</mi> <mi>n</mi> <mi>b</mi> <mi>e</mi> <mi>f</mi> <mi>o</mi> <mi>r</mi> <mi>e</mi> <mi>h</mi> <mi>i</mi> <mi>g</mi> <mi>h</mi> <mo>-</mo> <mi>i</mi> <mi>n</mi> <mi>c</mi> <mi>i</mi> <mi>d</mi> <mi>e</mi> <mi>n</mi> <mi>c</mi> <mi>e</mi> <mi>y</mi> <mi>e</mi> <mi>a</mi> <mi>r</mi> <mi>s</mi> <mi>c</mi> <mi>o</mi> <mi>u</mi> <mi>l</mi> <mi>d</mi> <mi>r</mi> <mi>e</mi> <mi>d</mi> <mi>u</mi> <mi>c</mi> <mi>e</mi> <mi>L</mi> <mi>y</mi> <mi>m</mi> <mi>e</mi> <mi>d</mi> <mi>i</mi> <mi>s</mi> <mi>e</mi> <mi>a</mi> <mi>s</mi> <mi>e</mi> <mi>c</mi> <mi>a</mi> <mi>s</mi> <mi>e</mi> <mi>s</mi> <mi>b</mi> <mi>y</mi> <mn>390</mn> <mi>t</mi> <mi>o</mi> <mn>787</mn> <mi>a</mi> <mi>n</mi> <mi>n</mi> <mi>u</mi> <mi>a</mi> <mi>l</mi> <mi>l</mi> <mi>y</mi> <mo>,</mo> <mi>s</mi> <mi>a</mi> <mi>v</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>u</mi> <mi>p</mi> <mi>t</mi> <mi>o</mi></math> 1.9 million in societal costs. <b>Discussion:</b> The simulations presented revealed substantial health and cost burden from Lyme disease, including hidden impacts from undiagnosed and unreported cases. Burden varied widely between high- and low-incidence years, highlighting the need to prioritize prevention when peak years are predicted. While we estimated the effects of individual prev","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"221-228"},"PeriodicalIF":2.3,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12640196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145587814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effect of a Digitally Delivered Conservative Musculoskeletal Care Program on Spinal Diagnostic Imaging Utilization in a Commercially Insured Population with Chronic Back Pain.","authors":"Louie Lu, Sandhya Yadav, Jeannie Bailey","doi":"10.36469/001c.145231","DOIUrl":"10.36469/001c.145231","url":null,"abstract":"<p><strong>Background: </strong>Conservative, noninvasive musculoskeletal treatment delivered digitally has demonstrated similar or better effectiveness in managing and reducing chronic back pain, compared to in-person care. However, there is limited evidence whether digital care reduces future spinal diagnostic imaging visits.</p><p><strong>Objectives: </strong>The primary goal was to examine the associations between participating in a digital conservative musculoskeletal care program for back pain and subsequent spinal diagnostic imaging use.</p><p><strong>Methods: </strong>Using medical claims data from a US commercial health plan database, this retrospective, secondary data analysis compared spinal diagnostic imaging visits among a group of digital program participants who had over 12 weeks of back pain to matched patients who only had usual care to treat their back pain. To mitigate selection bias, a propensity score matching model was developed to match study participants based on demographic, comorbidity, baseline medical care use and cost. The study outcomes were any spinal diagnostic imaging visit and number of spinal diagnostic imaging visits per 1000 participants up to 1 year after participating in the digital program.</p><p><strong>Results: </strong>The study included 2165 digital participants and 2165 matched comparison group patients. We found that digital participants had fewer spinal diagnostic imaging visits in the year after participating in the digital program compared with comparison group patients (14.2% vs 18.2%, <i>P</i> = .0003). The association between the digital program participation and spinal diagnostic imaging visit is stronger in the group who had imaging in the 12 months before, compared to those who had not (-4.8%, <i>P</i> = .007 vs -3.4%, <i>P</i> = .0163).</p><p><strong>Discussion: </strong>Consistent with previous studies demonstrating that early conservative management is associated with lower odds of imaging, findings from this study offer an encouraging direction for effective alternatives for managing back pain, improving performance outcomes and reducing premature utilization of healthcare services.</p><p><strong>Conclusion: </strong>The study provides evidence that participating in a digital musculoskeletal program that delivers conservative care is associated with fewer imaging use, especially among participants who had received imaging previously.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"200-208"},"PeriodicalIF":2.3,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12629400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of the Experimental EuroQol Toddler and Infant Populations (EQ-TIPS) and PedsQL in Infants and Toddlers with a Health Condition.","authors":"Janine Verstraete, Marco Zampoli, Alan Davidson, Marc Hendricks, Helder de Quintal, Yasmin Goga, Jo M Wilmshurst, Alvin Ndondo, Gillian Riordan, Ronalda De Lacy, Mignon McCullogh, Deveshni Reddy, Lasse Herdien","doi":"10.36469/001c.145813","DOIUrl":"10.36469/001c.145813","url":null,"abstract":"<p><strong>Background: </strong>Health-related quality of life measurement in infants and toddlers is increasingly important, but generic preference-weighted instruments lack evidence. This study compared the experimental EuroQol Toddler and Infant Populations (EQ-TIPS) and PedsQL in children 0 to 4 years.</p><p><strong>Methods: </strong>EQ-TIPS-3L v2.0 and PedsQL response distributions were compared by frequency. Item and dimension/summary score associations were computed using Pearson and intra-class correlation coefficient. Age and severity groups (EQ VAS ≥80) were compared with Mann-Whitney U tests.</p><p><strong>Results: </strong>Cross-sectional data from 260 children were analyzed: 0 to 24 months (n = 111) and 2 to 4 years (n = 149). Most caregivers were mothers, spending significantly more time (≥10 hours) with younger children χ2 = 18.12, <i>P</i> = .001). The EQ-TIPS-3L had the highest problems with eating (27%-31%) and pain (23%-25%) across age groups, with minimal missing data (≤1%). Younger children most frequently had problems with PedsQL: \"tired\" (54%), \"resting a lot\" (52%), \"crying or fussing when left alone\" (61%) and \"difficulty soothing when upset\" (51%). Older children's main problems were \"hurts or aches\" (54%), \"afraid or scared\" (53%), \"sad or blue\" (50%), \"angry\" (64%) and \"missing school\" (56%-65%). All 3 of the PedsQL school items had missing data for older children (27%-30%). Hypothesized item correlations were reached for 30 of 35 and 11 of 12 items in the younger and older groups, respectively. EQ-TIPS-3L LSS showed moderate to strong correlations with all PedsQL scores except for cognitive (0-24 months) and school functioning (2-4 years). Both measures significantly differentiated by severity groups (EQ VAS ≥80) but not by age group.</p><p><strong>Conclusion: </strong>Both measures showed similar response distributions despite different time frames and response scales. EQ-TIPS-3L eating and pain reported high problems, with eating strongly associated only with PedsQL physical symptoms. The 2- to 4-year PedsQL version had many missing school functioning items; the 13- to 24-month PedsQL may suit older 2- to 4-year-olds better. Low association between PedsQL cognitive functioning and EQ-TIPS-3L suggests further research is needed on this potentially missing construct.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"209-220"},"PeriodicalIF":2.3,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12629638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost Savings Associated With Fully Automated Digital Cognitive Behavioral Therapy for Insomnia Disorder (SleepioRx): A Matched Control Study of US Patients.","authors":"Christopher B Miller, Danielle Bradley, Shana Hall, Helen Hayes, Sulayman Chowdhury, Chris Sampson","doi":"10.36469/001c.146434","DOIUrl":"10.36469/001c.146434","url":null,"abstract":"<p><strong>Background: </strong>Insomnia affects up to one-third of US adults and is a significant health challenge with an estimated economic burden of up to $100 billion annually. Cognitive behavioral therapy (CBT) for insomnia (CBT-I) is the recommended first-line treatment, but access is limited due to a shortage of trained therapists. Digital CBT-I offers an effective alternative that may enhance accessibility and reduce higher healthcare costs associated with insomnia.</p><p><strong>Objective: </strong>To evaluate the US healthcare cost-savings of digital CBT-I compared with standard-of-care control.</p><p><strong>Methods: </strong>A retrospective difference-in-differences analysis compared 1-year preinitiation and post-initiation healthcare costs for 11 027 individuals receiving SleepioRx (FDA-cleared digital CBT treatment for insomnia disorder) compared with 1:1 exact matched controls with insomnia receiving standard care (n = 10 770). Commercial and Medicare claims were adjusted for comorbidities, index year, and baseline utilization.</p><p><strong>Results: </strong>Digital CBT-I was associated with statistically significant mean annual total cost savings of <math><mn>2083</mn> <mo>(</mo> <mn>95</mn></math> 1508-$2657, <i>P</i> < .001) per person, equating to a 42% reduction in costs with SleepioRx relative to matched controls who received standard of care (medications for insomnia).</p><p><strong>Discussion: </strong>Digital CBT-I was associated with substantial cost savings for payers. The integration of guideline-concordant treatment through digital delivery into standard care pathways offers a promising strategy to address the clinical and economic challenges of insomnia, supporting more efficient resource allocation.</p><p><strong>Conclusions: </strong>Findings suggest that implementing digital CBT-I at scale may lead to decreased costs for healthcare payers, relative to the current standard of care, while improving access to effective insomnia treatment.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"193-199"},"PeriodicalIF":2.3,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12619666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145540961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns, Clinical Events, and Costs of Care for Patients With Triple Negative Metastatic Breast Cancer: A Retrospective US Claims Database Study.","authors":"Manali Bhave, Tiffany Traina, Simon M Collin, Jenny Tse, Nazneen Fatima Shaikh, Dajun Tian, Aimee M Near","doi":"10.36469/001c.144499","DOIUrl":"10.36469/001c.144499","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy is the main treatment for patients with metastatic triple-negative breast cancer (mTNBC) who are ineligible for immunotherapy. TNBC is associated with poorer treatment outcomes than other breast cancer subtypes.</p><p><strong>Objective: </strong>To evaluate treatment patterns, quantify real-world healthcare costs and assess the burden of clinical events of interest (CEIs) among US patients with mTNBC who did not receive immunotherapy.</p><p><strong>Methods: </strong>This retrospective study used IQVIA PharMetrics® Plus healthcare claims data. Treatment-based proxies were used to identify patients first diagnosed with mTNBC from March 2017 to September 2023. Treatment regimens, frequency and incidence of CEIs, and all-cause, breast cancer-related, and CEI-related costs per patient per month (PPPM, including drug costs) were described during overall follow-up (any line of therapy [LOT]) and during LOT1 and LOT2.</p><p><strong>Results: </strong>A total of 2717 patients with mTNBC (99.1% female; mean±SD age, 55.6 ± 10.7 years) were identified. Over the follow-up period (median [Q1,Q3], 11.7 [6.0, 26.5] months), most patients (73.1%) only reached LOT1, and the remaining 26.9% of patients had multiple LOTs. Most patients had chemotherapy in LOT1 (98.1%) and LOT2 (90.6%); 98.5% had chemotherapy across any LOTs. Taxanes were the most common, observed in 74.8% of the overall cohort, followed by anthracyclines (56.4%). Across any LOT, 76.1% of patients had ≥1 CEI, most commonly hematological (49.5%), gastrointestinal (44.3%), infusion-related reactions (31.2%), and fatigue (27.8%). Mean (SD) all-cause total costs PPPM were <math><mn>14</mn> <mrow><mo> </mo></mrow> <mn>245</mn> <mo>(</mo></math> 12 776) overall (of which 79.6% were BC-related and 34.7% were CEI-related), <math><mn>17</mn> <mrow><mo> </mo></mrow> <mn>809</mn> <mo>(</mo></math> 18 806) during LOT1, and <math><mn>19</mn> <mrow><mo> </mo></mrow> <mn>797</mn> <mo>(</mo></math> 24 763) during LOT2.</p><p><strong>Discussion: </strong>Our study findings confirm previously reported high economic burden of mTNBC, with about 80% related to BC treatment. Most patients experienced CEIs during treatment, and these accounted for one-third of their total healthcare costs.</p><p><strong>Conclusions: </strong>Our study focused on patients with mTNBC with the greatest unmet need, namely those ineligible for immunotherapy. In patients with mTNBC, most of whom received chemotherapy as standard of care, CEIs presented both a clinical and economic burden, highlighting the need for newer treatments that balance total costs of care with adverse events and clinical benefit.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"183-192"},"PeriodicalIF":2.3,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Differences Between Manufacturers and Public Analyses in Health Technology Assessment in Japan.","authors":"Yoko Hirano, Akira Yuasa, Karin Matsumoto, Hiroshi Nakamura","doi":"10.36469/001c.144530","DOIUrl":"10.36469/001c.144530","url":null,"abstract":"<p><strong>Background: </strong>Japan has a unique drug pricing system that in principle reimburses all regulatory-approved drugs. To ensure sustainability, a health technology assessment (HTA) system was introduced in 2019 to adjust the prices of highly innovative and high-budget-impact drugs based on post-reimbursement cost-effectiveness evaluations.</p><p><strong>Objectives: </strong>This study aimed to examine the nature and contributing factors of differences between manufacturers' and public (the Center for Outcomes Research and Economic Evaluation for Health [C2H]) cost-effectiveness analyses for 31 products evaluated under the Japanese HTA system by March 2025.</p><p><strong>Methods: </strong>We conducted descriptive analyses comparing manufacturers' and C2H analyses using publicly available reports. Differences in the assessments of additional benefits, incremental cost-effectiveness ratios (ICERs), and reanalysis items were investigated. We explored issues related to orphan drugs and products granted usefulness premiums for attributes not fully captured by quality-adjusted life-years (QALYs), such as improved convenience and prolonged effect.</p><p><strong>Results: </strong>Among 74 analysis populations across 31 products, 48.6% showed inconsistencies between the manufacturers and C2H in the assessment of additional benefits, outcome measures, or analysis methods used to support those assessments. Inconsistencies in outcome measures and methods increased after the revision of the Japanese HTA system and its guidelines in April 2022. ICER differences were often linked to differences in quality-of-life (QOL) parameters and baseline assumptions. Products granted usefulness premiums for attributes not fully captured by QALYs showed greater ICER differences between the manufacturers and C2H than those without. Although manufacturers often rely on indirect treatment comparisons when evaluating orphan drugs due to limited data and the lack of comparators in clinical trials, these methods were less frequently accepted by C2H due to their associated uncertainty.</p><p><strong>Discussion: </strong>The findings highlight differences between the manufacturers' and C2H analyses, including evaluation of QOL, orphan drugs, and attributes not captured by QALYs. Providing clearer guidance, considering other countries' HTA systems, may help improve consistency in assessments.</p><p><strong>Conclusions: </strong>This study identified key differences and contributing factors under the Japanese HTA system. The findings are expected to inform future refinements of the system and its guidelines, thereby promoting more transparent and predictable evaluations.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 2","pages":"173-182"},"PeriodicalIF":2.3,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}